Serial Changes in Thyroid Hormones with Oral or Intravenous Bisphosphonates
Indian Journal of Endocrinology and Metabolism · 2026-03 · 30 (2) · 187-193
DOI: 10.4103/ijem.ijem_984_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Indian Journal of Endocrinology and Metabolism, online erschienen am 30.04.2026. Verfasst von Sandeep Kumar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Armed Forces Medical College, Pune, Maharashtra, India. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Bisphosphonates (BP) used in osteoporosis management can induce an acute phase response, their short-term endocrine effects remain unclear. This study hypothesized that initial BP exposure elicits a non-thyroidal illness syndrome (NTIS)-like pattern and that thyroid autoimmunity may amplify this response.
Methods
In this prospective cohort at a tertiary centre, 336 adults (93% postmenopausal women) were enrolled: 168 received first-dose BP therapy (zoledronic acid (ZA) =129; oral alendronate (ALN) = 39) and 168 matched controls (calcium/vitamin D). FT3, FT4, TSH, and erythrocyte sedimentation rate (ESR) were measured at baseline and on days 1, 2, 3, 7, and 42 with baseline anti-TPO Ab. Linear mixed-effects models with random intercepts evaluated group × time interactions, adjusting for age, sex, and body mass index.
Results
BP recipients demonstrated a clear temporal pattern, FT3 declined significantly, reaching a nadir on Day 2 (mean difference −0.47 pg/mL vs controls, P < 0.001), FT4 fell modestly (mean difference −0.07 ng/dL), and TSH was transiently suppressed before rebounding above baseline by Day 42 (mean difference +0.39 mIU/L). ESR peaked on Day 2 and normalized by Day 7, paralleling hormonal recovery. Group × time interactions were significant for all parameters ( P < 0.05). Anti-TPO Ab positive individuals exhibited deeper FT3 suppression and greater TSH rebound. ALN effects were directionally similar but underpowered.
Conclusion
First-dose BP therapy, particularly ZA, induces a short-lived, reversible NTIS-like response amplified by thyroid autoimmunity. Early post-infusion thyroid testing may mimic hypothyroidism, re-evaluation after six to eight weeks is recommended.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Armed Forces Medical College, Pune, Maharashtra, India.
- Department of Endocrinology, Manipal Hospital, Gurugram, Haryana, India.
- Magna Clinic, Hyderabad, Telangana, India.
- Commandant 167 Military Hospital, Pathankot, Punjab, India.
- Director of Endocrinology Paras Hospital, Panchkula, Haryana, India.
- Department of Endocrinology, Command Hospital (AF), Bengaluru, Karnataka, India.
Zitieren
APA
Kumar, S., Brar, K. S., Hari, K. K., Muthukrishnan, J., Kotwal, N., Malhotra, R., Bansal, N., Singh, S. K., & Sharma, P. (2026). Serial Changes in Thyroid Hormones with Oral or Intravenous Bisphosphonates. Indian Journal of Endocrinology and Metabolism, 30(2), 187-193. https://doi.org/10.4103/ijem.ijem_984_25
Vancouver
Kumar S, Brar KS, Hari KK, Muthukrishnan J, Kotwal N, Malhotra R, et al. Serial Changes in Thyroid Hormones with Oral or Intravenous Bisphosphonates. Indian Journal of Endocrinology and Metabolism. 2026;30(2):187-193. doi:10.4103/ijem.ijem_984_25
BibTeX
@article{Kumar2026,
author = {Kumar, Sandeep and Brar, Kiraninder S and Hari, Kumar Kvs and Muthukrishnan, Jayaraman and Kotwal, Narendra and Malhotra, Rakhi and Bansal, Naresh and Singh, Santosh K and Sharma, Prafull},
title = {Serial Changes in Thyroid Hormones with Oral or Intravenous Bisphosphonates},
journal = {Indian Journal of Endocrinology and Metabolism},
year = {2026},
volume = {30},
number = {2},
pages = {187--193},
doi = {10.4103/ijem.ijem_984_25}
}
EUVIMED